Foreign-invested pharmaceutical firms snatched up 16 reimbursed medicines exceeding 10.0 billion won

Of 30 reimbursed medicines exceeding 10.0 billion won in 2001, foreign-invested pharmaceutical firms accounted for 16 items, Rep. Kim Hong-shin said during the recent parliamentary inspection to Health Insurance Review Agency (HIRA).

Ref. Kim, who analyzed the HIRA data, disclosed that Pfizer Korea's Norvasc topped the list with 97.6 billion won, followed by Janssen Korea's Sporanox ca...